Literature DB >> 582863

Interindividual and interspecies variation in the metabolism of the hallucinogen 4-methoxyamphetamine.

I Kitchen, J Tremblay, J André, L G Dring, J R Idle, R L Smith, R T Williams.   

Abstract

1. The qualitative and quantitative aspects of the urinary elimination of orally administered 4-methoxy[14C]amphetamine have been examined in the rat and guinea-pig and in three volunteer human subjects, to determine interspecies and interindividual variations in disposition of the drug. 2. Both rat and guinea-pig excreted 70--80% of the administered dose(6 mg/kg) in the urine within 24 h, mainly as metabolites. 3. In the guinea-pig, the drug was metabolized by O-demethylation to give 4-hydroxyamphetamine, which was excreted free (4% dose) and conjugated (73%). No other metabolite was detected. 4. The rat metabolizes the drug both by O-dealkylation and by side-chain oxidation, the products being 4-hydroxyamphetamine (5% of dose free and 60% conjugated) and 1-(4'-methoxyphenyl)propan-2-one oxime (5% dose, free and conjugated). 5. In man the drug (dose 5 mg) is metabolized by O-demethylation and by side-chain oxidation. Marked intersubject variations were observed both in the array and quantitative aspects of metabolite excretion. Two subjects excreted mainly 4-hydroxyamphetamine (free and conjugated) together with smaller amounts of 1-(4'-methoxyphenyl)propan-2-one oxime and 4-hydroxynorephedrine. The third subject, however, who was previously known to exhibit a genetically determined defect in drug oxidation, was defective in O-dealkylation of 4-methoxyamphetamine, and the main excretion products were the unchanged drug together with products of side-chain oxidation, namely, 1-(4'-methoxyphenyl)propan-2-one oxime, 1-(4'-methoxyphenyl)propan-2-one and 4-methoxybenzoic acid. 6. Inter-individual differences in oxidative O-demethylation of the drug are discussed in relation to current theories on the aetiology of schizophrenia and reported fatalities arising from abuse of the drug.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 582863     DOI: 10.3109/00498257909038744

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  13 in total

1.  Clinical significance of the sparteine/debrisoquine oxidation polymorphism.

Authors:  K Brøsen; L F Gram
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

2.  Contribution of the genetic status of oxidative metabolism to variability in the plasma concentrations of beta-adrenoceptor blocking agents.

Authors:  P Dayer; L Balant; A Küpfer; F Courvoisier; J Fabre
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 3.  Assessment of the drug metabolism capacity of the liver.

Authors:  B K Park
Journal:  Br J Clin Pharmacol       Date:  1982-11       Impact factor: 4.335

4.  The contribution of genetically determined oxidation status to inter-individual variation in phenacetin disposition.

Authors:  H W Devonshire; I Kong; M Cooper; T P Sloan; J R Idle; R L Smith
Journal:  Br J Clin Pharmacol       Date:  1983-08       Impact factor: 4.335

5.  A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

Authors:  D A Evans; A Mahgoub; T P Sloan; J R Idle; R L Smith
Journal:  J Med Genet       Date:  1980-04       Impact factor: 6.318

6.  Polymorphic metabolism of beta-adrenoceptor antagonists.

Authors:  J H Silas; M S Lennard; G T Tucker; L E Ramsay; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1984       Impact factor: 4.335

7.  Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone.

Authors:  D Wu; S V Otton; B A Sproule; U Busto; T Inaba; W Kalow; E M Sellers
Journal:  Br J Clin Pharmacol       Date:  1993-01       Impact factor: 4.335

8.  Assay and characterisation of debrisoquine 4-hydroxylase activity of microsomal fractions of human liver.

Authors:  G C Kahn; A R Boobis; S Murray; M J Brodie; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1982-05       Impact factor: 4.335

Review 9.  Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices.

Authors:  Rafael de la Torre; Magí Farré; Mónica Navarro; Roberta Pacifici; Piergiorgio Zuccaro; Simona Pichini
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 10.  P450 enzymes. Inhibition mechanisms, genetic regulation and effects of liver disease.

Authors:  M Murray
Journal:  Clin Pharmacokinet       Date:  1992-08       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.